Survey by the French Medicine Agency (ANSM) of the imaging protocol, detection rate, and safety of Ga-PSMA-11 PET/CT in the biochemical recurrence of prostate cancer in case of negative or equivocal F-fluorocholine PET/CT: 1084 examinations.

Fiche publication

Date publication

août 2021

Journal

European journal of nuclear medicine and molecular imaging

Auteurs

Membres identifiés du Cancéropôle Est :
Dr BOUDALI Lotfi

Tous les auteurs :
Chevalme YM, Boudali L, Gauthé M, Rousseau C, Skanjeti A, Merlin C, Robin P, Giraudet AL, Janier M, Talbot JN

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/33416958

Résumé

Despite growing evidence of a superior diagnostic performance of Ga-PSMA-11 over F-fluorocholine (FCH) PET/CT, the number of PET/CT centres able to label on site with gallium-68 is still currently limited. Therefore, patients with biochemical recurrence (BCR) of prostate cancer frequently undergo FCH as the 1st-line PET/CT. Actually, the positivity rate (PR) of a second-line PSMA-11 PET/CT in case of negative FCH PET/CT has only been reported in few short series, in a total of 185 patients. Our aims were to check (1) whether the excellent PR reported with PSMA-11 is also obtained in BCR patients whose recent FCH PET/CT was negative or equivocal; (2) in which biochemical and clinical context a high PSMA-11 PET/CT PR may be expected in those patients, in particular revealing an oligometastatic pattern; (3) whether among the various imaging protocols for PSMA-11 PET/CT used in France, one yields a significantly highest PR; (4) the tolerance of PSMA-11.